Recent content by KKGG

  1. KKGG

    Cilcare's CIL001 Targets Cochlear Synaptopathy — An American/French Collaboration

    I believe the reasoning behind conducting a trial with people who have diabetes and neurodegenerative issues is to focus on individuals with a high likelihood of small fiber neuropathy-related hearing loss. This condition would likely also present as synaptopathy. Since synaptopathy is difficult...
  2. KKGG

    Frequency Therapeutics — FX-345

    More and more research and the beginnings of clinical studies are emerging every week and month. Cilcare shows promise, as does Rinri Therapeutics. Mass Eye and Ear made impressive advancements this year. Here’s to a hopeful 2025!